Our Blog
Videos
DistributorsFor Veterinarians
As a veterinarian you want only the best for your "patients". You want to be able to offer your "patients" advanced wound and infection care that limits risks and does not encourage the increasing number of antibiotic-resistant bacteria. Please take a few minutes to study the science behind the family of Vetericyn products formulated with our technology. If you have any questions, or would like further data, please feel free to contact us.
Vetericyn’s mode of action
Vetericyn’s mode of action against microorganisms mimics that of neutrophils in the body. Specifically, the hypochlorous acid (HOCl) that is generated through the oxidative burst process of neutrophils acts as a potent antimicrobial agent which attacks only single cell pathogens. As a strong oxidant, hypochlorous acid is known to react through a variety of pathways with biomolecules. However, the main route of attack against microorganisms is the disruption of the cellular membrane.
Neutrophils are the most abundant type of white blood cells in humans (comprising about 50-70% of all white blood cells) and form an integral part of the immune system as neutrophils are the first human cells arrive at a site of infection through a process known as chemotaxis. As demonstrated in the video above, a human neutrophil senses and moves toward a yeast cell. Next, it surrounds and digests the yeast cell. The neutrophil uses an oxidative or respiratory burst to produce a number of active ingredients including hypochlorous acid to kill the yeast.
Vetericyn Manufacturing and Ingredients
Our technology utilizes a unique multi-chamber electrolysis manufacturing process in which purified water containing trace amounts of sodium chloride (NaCl) is oxidized creating a proprietary solution of oxidized water and oxychlorine species.
The Science Behind Our Technology
Our technology is a unique, shelf-stable, pH-neutral oxychlorine compound which has been studied for its clinical benefits and safety. A number of these findings have been peer-reviewed and published. These studies demonstrate that our technology delivers wound healing benefits, reduction of inflammation and cure or improvement of infection; all while remaining safe and biocompatible as evidenced in a 2007 study published in the International Wound Journal. The reason for this safety is that mammalian cells have evolved with special pumps to regulate the active ingredients in our technology while viruses, fungi, spores and bacteria, including drug-resistant bacteria, lack this ability.
One of our technologies primary modes of action (proven via in vitro tests)is its ability to treat a wide range of pathogens, including antibiotic-resistant strains of bacteria (including MRSA and VRE), viruses and fungi, as it is described in a study published in May/June 2006 issue of Diabetic Microvascular Complications Today. It has also been demonstrated in research studies that Microcyn induces vasodilatation and inhibits inflammation.
Our technology chemistry mimics the same oxychlorine composition as that manufactured by Neutrophils in the body's immune system.
The preceding data is based upon testing done on the Microcyn® Technology platform and does not necessarily infer that similar data would be generated in testing on various Microcyn-based products or formulas under development.
View Mobile Site